{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T08:25:23Z","timestamp":1746174323906},"reference-count":29,"publisher":"Japan Endocrine Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2018]]},"DOI":"10.1507\/endocrj.ej17-0268","type":"journal-article","created":{"date-parts":[[2017,12,26]],"date-time":"2017-12-26T22:14:07Z","timestamp":1514326447000},"page":"307-315","source":"Crossref","is-referenced-by-count":6,"title":["Broad clinical spectrum and diverse outcomes of prolactinoma with pediatric onset: medication-resistant and recurrent cases"],"prefix":"10.1507","volume":"65","author":[{"given":"Yoo-Mi","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Pusan National University School of Medicine, Pusan National University Children\u2019s Hospital, Yangsan, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Go Hun","family":"Seo","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Asan Medical Center Children\u2019s Hospital, University of Ulsan College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoon-Myung","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Asan Medical Center Children\u2019s Hospital, University of Ulsan College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Ho","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Asan Medical Center Children\u2019s Hospital, University of Ulsan College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han-Wook","family":"Yoo","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Asan Medical Center Children\u2019s Hospital, University of Ulsan College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Colao A, Savastano S (2011) Medical treatment of prolactinomas. Nat Rev Endocrinol 7: 267\u2013278.","DOI":"10.1038\/nrendo.2011.37"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2 Ciccarelli A, Daly AF, Beckers A (2005) The epidemiology of prolactinomas. Pituitary 8: 3\u20136.","DOI":"10.1007\/s11102-005-5079-0"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Colao A (2009) Pituitary tumours: the prolactinoma. Best Pract Res Clin Endocrinol Metab 23: 575\u2013596.","DOI":"10.1016\/j.beem.2009.05.003"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Lafferty AR, Chrousos GP (1999) Pituitary tumors in children and adolescents. J Clin Endocrinol Metab 84: 4317\u20134323.","DOI":"10.1210\/jcem.84.12.6215"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Cannav\u00f2 S, Venturino M, Curt\u00f2 L, De Menis E, D\u2019Arrigo C, et al. (2003) Clinical presentation and outcome of pituitary adenomas in teenagers. Clin Endocrinol (Oxf) 58: 519\u2013527.","DOI":"10.1046\/j.1365-2265.2003.01748.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Salenave S, Ancelle D, Bahougne T, Raverot G, Kamenick\u00fd P, et al. (2015) Macroprolactinomas in children and adolescents: factors associated with the response to treatment in 77 patients. J Clin Endocrinol Metab 100: 1177\u20131186.","DOI":"10.1210\/jc.2014-3670"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, et al. (2011) Endocrine Society: diagnosis and treatment of hyperprolactinoma. J Clin Endocrinol Metab 96: 273\u2013288.","DOI":"10.1210\/jc.2010-1692"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Colao A, Loche S, Cappa M, Di Sarno A, Landi ML, et al. (1998) Prolactinomas in children and adolescents: clinical presentation and long-term follow-up. J Clin Endocrinol Metab 83: 2777\u20132780.","DOI":"10.1210\/jcem.83.8.5001"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Cook DM (2005) Long-term management of prolactinomas: use of long-acting dopamine agonists. Rev Endocr Metab Disord 6: 15\u201321.","DOI":"10.1007\/s11154-005-5220-4"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Wong A, Eloy JA, Couldwell WT, Liu JK (2015) Update on prolactinomas, part 2: treatment and management strategies. J Clin Neurosci 22: 1568\u20131574.","DOI":"10.1016\/j.jocn.2015.03.059"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Moraes AB, Silva CM, Vieira Neto L, Gadelha MR (2013) Giant prolactinomas: the therapeutic approach. Clin Endocrinol (Oxf) 79: 447\u2013456.","DOI":"10.1111\/cen.12242"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Maiter D, Delgrange E (2014) Therapy of endocrine disease: the challenges in managing giant prolactinomas. Eur J Endocrinol 170: R213\u2013R227.","DOI":"10.1530\/EJE-14-0013"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Palmert MR, Dunkel L (2012) Clinical practice: delayed puberty. N Engl J Med 366: 443\u2013453.","DOI":"10.1056\/NEJMcp1109290"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, et al. (2001) Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 86: 5256\u20135261.","DOI":"10.1210\/jcem.86.11.8054"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Laway BA, Mir SA, Bhat JR, Lone MI, Samoon J, et al. (2012) Hematological response of pancytopenia to glucocorticoids in patients with Sheehan\u2019s syndrome. Pituitary 15: 184\u2013187.","DOI":"10.1007\/s11102-011-0304-5"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Lang D, Mead JS, Sykes DB (2015) Hormones and the bone marrow: panhypopituitarism and pancytopenia in a man with a pituitary adenoma. J Gen Intern Med 30: 692\u2013696.","DOI":"10.1007\/s11606-014-3161-x"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Doknic M, Pekic S, Zarkovic M, Medic-Stojanoska M, Dieguez C, et al. (2002) Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur J Endocrinol 147: 77\u201384.","DOI":"10.1530\/eje.0.1470077"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Kim K, Yun SH, Jang MJ, Oh KW (2013) Body fat percentile curves for Korean children and adolescents: a data from the Korea National Health and Nutrition Examination Survey 2009\u20132010. J Korean Med Sci 28: 443\u2013449.","DOI":"10.3346\/jkms.2013.28.3.443"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Anagnostis P, Adamidou F, Polyzos SA, Efstathiadou Z, Karathanassi E, et al. (2012) Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: a single center experience. Pituitary 15: 25\u201329.","DOI":"10.1007\/s11102-011-0303-6"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Dekkers OM, Lagro J, Burman P, J\u00f8rgensen JO, Romijn JA, et al. (2010) Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab 95: 43\u201351.","DOI":"10.1210\/jc.2009-1238"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Barber TM, Kenkre J, Garnett C, Scott RV, Byrne JV, et al. (2011) Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma. Clin Endocrinol (Oxf) 75: 819\u2013824.","DOI":"10.1111\/j.1365-2265.2011.04136.x"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Vroonen L, Jaffrain-Rea ML, Petrossians P, Tamagno G, Chanson P, et al. (2012) Prolactinomas resistant to stan\u00addard doses of cabergoline: a multicenter study of 92 patients. Eur J Endocrinol 167: 651\u2013662.","DOI":"10.1530\/EJE-12-0236"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Delgrange E, Daems T, Verhelst J, Abs R, Maiter D (2009) Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur J Endocrinol 160: 747\u2013752.","DOI":"10.1530\/EJE-09-0012"},{"key":"24","doi-asserted-by":"crossref","unstructured":"25 Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J (1997) Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 82: 2102\u20132107.","DOI":"10.1210\/jc.82.7.2102"},{"key":"25","doi-asserted-by":"crossref","unstructured":"26 Nishioka H, Haraoka J, Akada K (2003) Growth potential of prolactinomas in men: is it really different from women? Surg Neurol 59: 386\u2013390.","DOI":"10.1016\/S0090-3019(03)00012-0"},{"key":"26","doi-asserted-by":"crossref","unstructured":"27 Acharya SV, Gopal RA, Bandgar TR, Joshi SR, Menon PS, et al. (2009) Clinical profile and long term follow up of children and adolescents with prolactinomas. Pituitary 12: 186\u2013189.","DOI":"10.1007\/s11102-008-0149-8"},{"key":"27","doi-asserted-by":"crossref","unstructured":"28 Kurosaki M, Kambe A, Ishibashi M, Watanabe T, Horie Y (2014) Case report of sarcoma of the sella caused by postoperative radiotherapy for a prolactin-producing pituitary adenoma. Brain Tumor Pathol 31: 187\u2013191.","DOI":"10.1007\/s10014-014-0175-3"},{"key":"28","doi-asserted-by":"crossref","unstructured":"29 Behan LA, Draman MS, Moran C, King T, Crowley RK, et al. (2011) Secondary resistance to cabergoline therapy in a macroprolactinoma: a case report and literature review. Pituitary 14: 362\u2013366.","DOI":"10.1007\/s11102-009-0168-0"},{"key":"29","doi-asserted-by":"crossref","unstructured":"30 Felker J, Patterson B, Wrubel D, Janss A (2016) Successful treatment of a child with a prolactin secreting macro\u00adadenoma with temozolomide. J Pediatr Endocrinol Metab 29: 1413\u20131415.","DOI":"10.1515\/jpem-2016-0159"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/65\/3\/65_EJ17-0268\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T18:29:14Z","timestamp":1570559354000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/65\/3\/65_EJ17-0268\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej17-0268","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}